We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Transfused RBCs Rapidly Recover From Metabolic Storage Lesions

By LabMedica International staff writers
Posted on 20 Jul 2022
Print article
Image: Storage of red blood cells in alkaline PAGGGM improves metabolism but has no effect on recovery after transfusion (Photo courtesy of openPR)
Image: Storage of red blood cells in alkaline PAGGGM improves metabolism but has no effect on recovery after transfusion (Photo courtesy of openPR)

Directly after red blood cell (RBC) transfusion, a significant number of RBCs are cleared from the circulation; in some patients, up to 38% of the transfused RBCs are cleared in the first 24 hours.

During storage, RBCs undergo several metabolic and morphological changes, known as the “storage lesion.” The metabolic changes include decreased cellular levels of 2,3-diphosphoglycerate (2,3-DPG), adenosine triphosphate (ATP), and impaired redox metabolism. Decrease in the intracellular pH contributes significantly to the storage lesion.

Hematologists at the University of Amsterdam (Amsterdam, The Netherlands) conducted an open-label randomized controlled trial to study the effect of storage time and additive solution on the post-transfusion recovery (PTR) of RBCs. Twenty healthy male subjects were recruited who donated 500 mL and 200 mL of whole blood in citrate-phosphate-dextrose (CPD) at the national blood bank 35 and two days before the transfusion, respectively.

In this trial the effect of storage, phosphate-adenine-glucose-guanosine-gluconate-mannitol (PAGGGM) versus saline-adenine-glucose-mannitol (SAGM), on post-transfusion recovery (PTR) and metabolic restoration after transfusion was assessed. Subjects received an autologous biotinylated RBC concentrate stored for 35 days in SAGM or PAGGGM. As a reference for the PTR, a 2-day stored autologous biotinylated RBC concentrate stored in SAGM was simultaneously transfused. RBC phenotype and PTR were assessed after transfusion.

EDTA anti-coagulated blood samples were analyzed one day after sampling. The amount of bioRBCs was quantified by flow cytometry after staining with Streptavidin Alexa Fluor 647 conjugate. All flow cytometry experiments were performed with a flow cytometer: BD FACS, BD Fortessa + High Throughput Sampler (HTS), (BD Biosciences, San Jose, CA, USA). BioRBCs were isolated in two separate steps from the EDTA whole blood samples. This procedure was based on the differences in biotin density. In the first step, bioRBCs were isolated using magnetic beads, followed by the second step using flow cytometric cell sorting. Ultra-high pressure liquid chromatography–mass spectrometry analyses were performed using a Vanquish UHPLC coupled online to a Q Exactive mass spectrometer (Thermo Fisher, Bremen, Germany).

The investigators reported that the PTR was significantly higher in the 2-day stored RBCs than in 35-day stored RBCs two and seven days after transfusion: 96% (range 90% to 99%) versus 72% (66% to 89%) and 96% (90% to 99%) versus 72% (66% to 89%), respectively. PTR of SAGM- and PAGGGM-stored RBCs did not differ significantly. Glucose and redox metabolism were better preserved in PAGGGM-stored RBCs. The differences measured in the blood bag remained present only until one day after transfusion. No differences in RBC phenotype were found besides an increased complement C3 deposition on 35-day RBCs stored in PAGGGM.

The authors concluded that despite a better metabolic profile of PAGGGM RBCs, PAGGGM storage did not lead to a higher PTR. Therefore, storage PAGGGM is not a superior alternative for storage in SAGM. Furthermore, the metabolic storage lesion was corrected within a day after transfusion. Finally, 35 days of storage resulted in a lower PTR compared with two days of storage. The study was published on July 6, 2022 in the journal Blood Advances.

Related Links:
University of Amsterdam 
BD Biosciences 
Thermo Fisher 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more